TokenPost·
Teva Sets 2030 Innovative Medicines Revenue Target at $6 Billion to $7 Billion
Teva presented the target at its Nov. 11 R&D Day.
More news
- TokenPostBitwise CIO Matt Hougan Compares Hyperliquid’s Expansion to Amazon
- TokenPostU.S. 10-Year Treasury Yield Expected to Hold at 5% for Three Months
- TokenPostRox Raises $100 Million in Series B at $1.3 Billion Valuation
- TokenPostAnthropic Sets Nasdaq IPO Window for Nov. 19 or 20 Under Ticker ANT
- TokenPostEther Falls Below $2,050 as Binance Spot Price Reaches $2,049
- TokenPostTether’s 0.8B BotPsy Beats Larger Model in Five of Six AI Tests